SLAM family member 7Genealiases: 19A · CD319 · CRACC · CS1
Q-omics provides the consensus-scored SLAMF7 profile across patient tissues and cancer cell-line models. SLAMF7 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, SLAMF7 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, SLAMF7 RNA expression shows 17,700 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, KIRC, and LSCC as cancer lineages where SLAMF7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLAMF7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLAMF7 survival associations across molecular data types. SLAMF7 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLAMF7 RNA expression–survival associations across cancer types. High SLAMF7 expression shows favorable associations in SKCM, OV, HNSC, CESC, BRCA and LIHC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for SLAMF7 RNA expression.
This table summarizes SLAMF7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SLAMF7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLAMF7 shows lower tumor expression in COAD and READ and higher tumor expression in KIRC, HNSC, LUAD and KIRP. The KIRC box plot shows higher SLAMF7 RNA expression in tumor versus normal tissue (log2 FC = +2.377, t-test p < 0.001).
This table shows molecular features associated with SLAMF7 in patient tissues and cancer cell lines. In patient samples, SLAMF7 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SLAMF7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LUNG_NSCLC_LUAD.
